. Author manuscript; available in PMC: 2016 Apr 1.

Published in final edited form as: J Clin Exp Ophthalmol. 2015 Apr 27;6(2):422. doi: 10.4172/2155-9570.1000422

Table 3.

Benefits of methotrexate therapy for TED.

	Number of patients
Patients on prednisone at start of trial	14
Patients able to reduce prednisone dosage to zero	9 out of 14 (64%)
Patients with reduced visual acuity at start of trial	12 (86%)
Patients able to improve acuity by at least two lines	7 out of 12 (58%)
Patients with abnormal exophthalmometry	10 (71%)
Patients with improved exophthalmometry at the end of trial	3 out of 10 (30%)
Patients with EOMs restriction	13 (93%)
Patients with improved EOMs at the end of trial	5 out of 13 (38%)